- Total revenues: $6.9M (-72.4%), license & milestone fees: $0.3M, Kadycla royalty payments: $2.6M, R&D support fees: $1.9M, clinical materials revenue: $2.1M.
- Operating expenses: $44.3M (+68.4%).
- Cash and equivalents as of March 31: $164.1M.
- CF Ops (9 months): -$34.7M (+28.7%).
- Updated guidance for FY14:
- Revenues: $60M - $64M.
- Operating expenses: $133M - $137M.
- Net loss: -$71M - -$75M.
- CF Ops: -$56M - -$60M.
- CAPEX: $8M - $10M.
- Cash and equivalents at fiscal year end: $134M - $138M.
- (NASDAQ:IMGN)